Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study
Open Access
- 1 May 2020
- journal article
- research article
- Published by Elsevier BV in Thrombosis Research
- Vol. 189, 96-101
- https://doi.org/10.1016/j.thromres.2020.03.005
Abstract
No abstract availableKeywords
Funding Information
- Pharmaceuticals Bayer
This publication has 21 references indexed in Scilit:
- When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTHJournal of Thrombosis and Haemostasis, 2016
- Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia AHaemophilia, 2015
- Long‐term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight ® ) in previously treated patients with severe haemophilia A: interim results of the guardian ™ 2 extension trialHaemophilia, 2015
- Pharmacokinetic properties of BAY 81‐8973, a full‐length recombinant factor VIIIHaemophilia, 2015
- Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)Journal of Thrombosis and Haemostasis, 2014
- Controlled, cross‐sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demandHaemophilia, 2014
- Guidelines for the management of hemophiliaHaemophilia, 2012
- A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)Journal of Thrombosis and Haemostasis, 2011
- Challenges of defining reliable clinical surrogate end points in haemophilia trials: a critical reviewBlood Coagulation & Fibrinolysis, 2009
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaThe New England Journal of Medicine, 2007